CUE250117P1000
- 0.15
- 0.000.00%
Cue Biopharma Newsroom
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Analysts Are Bullish on These Healthcare Stocks: Hookipa Pharma (HOOK), Cue Biopharma (CUE)
Cue Biopharma's Nasdaq Compliance Struggle: Risks and Implications for Future Stability
Express News | Cue Biopharma Inc : Jefferies Cuts Target Price to $4 From $6
Stifel Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $4
Stifel Nicolaus Remains a Buy on Cue Biopharma (CUE)
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
Cue Biopharma Reports Q3 EPS (17c), Consensus (19c)
Cue Biopharma | 10-Q: Q3 2024 Earnings Report
Cue Biopharma | 8-K: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Cue Biopharma, Inc. Q3 Operating Expenses USD 12.151 Million
Express News | Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Biopharma 3Q Loss/Shr 17c >CUE
Press Release: Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Cue Names Daniel Baker Interim CDO, CSO Amish Suri to Transition to Advisor Role
Express News | Cue Biopharma Inc: Daniel Baker Will Join as Interim Chief Development Officer
Express News | Cue Biopharma Announces Strategic Organizational Transition
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference